JP2023541928A5 - - Google Patents

Info

Publication number
JP2023541928A5
JP2023541928A5 JP2023516800A JP2023516800A JP2023541928A5 JP 2023541928 A5 JP2023541928 A5 JP 2023541928A5 JP 2023516800 A JP2023516800 A JP 2023516800A JP 2023516800 A JP2023516800 A JP 2023516800A JP 2023541928 A5 JP2023541928 A5 JP 2023541928A5
Authority
JP
Japan
Prior art keywords
patent document
application publication
release
patent application
document
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541928A (ja
Filing date
Publication date
Priority claimed from US17/028,403 external-priority patent/US11684596B2/en
Application filed filed Critical
Publication of JP2023541928A publication Critical patent/JP2023541928A/ja
Publication of JP2023541928A5 publication Critical patent/JP2023541928A5/ja
Pending legal-status Critical Current

Links

JP2023516800A 2020-09-22 2021-08-27 抗糖尿病医薬組成物およびその調製方法 Pending JP2023541928A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/028,403 US11684596B2 (en) 2020-09-22 2020-09-22 Antidiabetic pharmaceutical compositions and preparation method thereof
US17/028,403 2020-09-22
PCT/US2021/048104 WO2022066363A1 (en) 2020-09-22 2021-08-27 Antidiabetic pharmaceutical compositions and preparation method thereof

Publications (2)

Publication Number Publication Date
JP2023541928A JP2023541928A (ja) 2023-10-04
JP2023541928A5 true JP2023541928A5 (cg-RX-API-DMAC7.html) 2024-09-03

Family

ID=80739639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516800A Pending JP2023541928A (ja) 2020-09-22 2021-08-27 抗糖尿病医薬組成物およびその調製方法

Country Status (9)

Country Link
US (1) US11684596B2 (cg-RX-API-DMAC7.html)
EP (1) EP4216942A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023541928A (cg-RX-API-DMAC7.html)
KR (1) KR20230093255A (cg-RX-API-DMAC7.html)
CN (1) CN114929210A (cg-RX-API-DMAC7.html)
AU (1) AU2021349178A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023005228A2 (cg-RX-API-DMAC7.html)
CA (1) CA3192584A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022066363A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20250096A (es) * 2022-08-24 2025-06-27 Dong A St Co Ltd Formulación oral compuesta que comprende evogliptina y metformina y método de preparación de la misma
US20240374542A1 (en) * 2023-05-10 2024-11-14 Elite Pharmaceutical Solution Inc. Oral dosage forms of metformin and preparation method thereof
CN121586575A (zh) * 2023-05-10 2026-02-27 赛乐医药科技有限公司 二甲双胍口服剂型及其制备方法
CN122438678A (zh) 2023-12-22 2026-07-21 新梅斯托克公司 包含达格列净和二甲双胍的双层片剂制剂
KR20250154775A (ko) * 2024-04-22 2025-10-29 제이피바이오 주식회사 다파글리플로진, 리나글립틴 및 메트포르민을 포함하는 안정성이 향상된 약제학적 제제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
ES2529180T3 (es) * 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
DE602004032149D1 (de) * 2003-09-26 2011-05-19 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
AU2009220444A1 (en) * 2008-03-04 2009-09-11 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
CN101940578B (zh) * 2010-08-25 2012-07-25 山东新华制药股份有限公司 一种用于治疗2型糖尿病的药物组合物及其制备方法
CN101984974B (zh) * 2010-11-15 2013-04-17 山东新华制药股份有限公司 一种用于治疗2型糖尿病的药物组合物的制备方法
CN105663130B (zh) * 2011-04-15 2019-08-09 江苏豪森药业集团有限公司 一种具有第一和第二活性药物的制剂
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CN103285398B (zh) * 2013-06-28 2015-07-22 青岛黄海制药有限责任公司 含有dpp-ⅳ抑制剂和第二种糖尿病药物的复方制剂及其制备方法
CN103933031B (zh) * 2014-05-13 2017-01-18 中国药科大学 一种含有dpp‑4抑制剂和盐酸二甲双胍的复方制剂及其制备方法
CN105878256B (zh) * 2015-01-05 2019-10-22 合肥立方制药股份有限公司 含有盐酸二甲双胍和格列美脲的控释制剂及其制备方法
CN104940159B (zh) * 2015-07-15 2018-09-18 山东司邦得制药有限公司 一种盐酸二甲双胍控释片及其制备方法与应用
US10987311B2 (en) * 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US20200289420A1 (en) * 2019-03-17 2020-09-17 Elite Pharmaceutical Solution Inc. Pharmaceutical compositions for treating diabetes and preparation method thereof

Similar Documents

Publication Publication Date Title
JP2008523153A5 (cg-RX-API-DMAC7.html)
JP2021524958A5 (cg-RX-API-DMAC7.html)
JP2019513799A5 (cg-RX-API-DMAC7.html)
JP2019530713A5 (cg-RX-API-DMAC7.html)
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
EA200400664A1 (ru) Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii
JP2005518433A5 (cg-RX-API-DMAC7.html)
WO2002002638A3 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2005105141A3 (en) Combined meningococcal conjugates with common carrier protein
JP2023166406A5 (cg-RX-API-DMAC7.html)
JP2005531614A5 (cg-RX-API-DMAC7.html)
JP2022510882A5 (cg-RX-API-DMAC7.html)
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
JP2018529666A5 (cg-RX-API-DMAC7.html)
CR9363A (es) Composiciones para la transmision transmucosa oral de la metformina
JP2014521641A5 (cg-RX-API-DMAC7.html)
JP2020536098A5 (cg-RX-API-DMAC7.html)
JP2023549849A5 (cg-RX-API-DMAC7.html)
JP2025508976A5 (cg-RX-API-DMAC7.html)
PE20020387A1 (es) Uso de una combinacion de salmeterol y fluticasona
JP2025509278A5 (cg-RX-API-DMAC7.html)
CA2620065A1 (en) Methods and formulations for modulating lyn kinase activity and treating related disorders
JP2023521031A5 (cg-RX-API-DMAC7.html)
JP2022512158A5 (cg-RX-API-DMAC7.html)
RU2006127422A (ru) Антимикробные консерванты для достижения мультидозовых рецептур с использованием бета-циклодекстринов для жидких лекарственных форм